US to Implement Staged Tariffs on Generic Drug Imports After Two-Year Exemption
- US imposes 2-year zero tariffs on generic drugs starting Aug 1, 2026.
- Tariffs to hit 100% after exemption, then 200% permanently.
- Aims to boost US production in $500B global generic drug market.
The Trump administration has unveiled a new tariff schedule for imported generic drugs, initiating a two-year period of zero tariffs starting August 1. Following this initial exemption, a 100% levy will be applied in August 2028, escalating further to 200% by August 2029. This phased approach is designed to encourage generic drug manufacturers to relocate production to the United States, a sector previously exempted from broader pharmaceutical tariffs. The policy has reportedly caused apprehension among major generic drug exporters, particularly Indian manufacturers, who rely heavily on the US market. Given that generic drugs constitute the majority of US prescriptions and typically operate on narrow profit margins, significant adjustments to global supply chains are anticipated.
President Donald Trump has announced the specific schedule for tariffs on imported generic drugs, confirming a two-year exemption period. The zero-tariff period is set to begin on August 1st, 2026, lasting for two years. Following this, a 100% tariff will be imposed for one year, escalating to 200% thereafter. The administration’s stated goal is to provide manufacturers time to invest in U.S. production and bring pharmaceutical manufacturing back to the country. The global generic drug industry is valued at nearly $500 billion. Trump made the announcement on Truth Social.